Open AccessLong‐term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta‐analysis
Author(s) -
Sardar Partha,
Kundu Amartya,
Chatterjee Saurav,
Nohria Anju,
Nairooz Ramez,
Bangalore Sripal,
Mukherjee Debabrata,
Aronow Wilbert S.,
Lavie Carl J
Publication year - 2017
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22631
Subject(s) - medicine , breast cancer , relative risk , meta analysis , hazard ratio , confidence interval , cancer , radiation therapy , oncology
Background Radiotherapy ( RT ) is frequently associated with late cardiovascular ( CV ) complications. The mean cardiac dose from irradiation of a left‐sided breast cancer is much higher than that for a right‐sided breast cancer. However, data is limited on the long‐term risks of RT on CV mortality. Hypothesis RT for breast cancer is associated with long term CV mortality and left sided RT carries a greater mortality than right sided RT . Methods We searched PubMed , Cochrane Central, Embase, EBSCO , Web of Science, and CINAHL databases from inception through December 2015. Studies reporting CV mortality with RT for left‐ vs right‐sided breast cancers were included. The principal outcome of interest was CV mortality. We calculated summary risk ratio ( RR ) and 95% confidence intervals ( CI ) with the random‐effects model. Results The analysis included 289 109 patients from 13 observational studies. Women who had received RT for left‐sided breast cancer had a higher risk of CV death than those who received RT for a right‐sided breast cancer ( RR : 1.12, 95% CI : 1.07‐1.18, P < 0.001; number needed to harm: 353). Difference in CV mortality between left‐ vs right‐sided breast RT was more apparent after 15 years of follow‐up ( RR : 1.23, 95% CI : 1.08‐1.41, P < 0.001; number needed to harm: 95). Conclusions CV mortality from left‐sided RT was significantly higher compared with right‐sided RT for breast cancer and was more apparent after ≥15 years of follow‐up.